Isepamicin
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Isepamicin
- DrugBank Accession Number
- DB13540
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 569.6031
Monoisotopic: 569.290821865 - Chemical Formula
- C22H43N5O12
- Synonyms
- HAPA-B
- HAPA-gentamycin B
- Isepamicin
- Isepamicina
- Isepamicinum
- External IDs
- Sch 21420
- SCH-21420
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Abacavir may decrease the excretion rate of Isepamicin which could result in a higher serum level. Aceclofenac Aceclofenac may decrease the excretion rate of Isepamicin which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Isepamicin which could result in a higher serum level. Acenocoumarol The risk or severity of bleeding can be increased when Isepamicin is combined with Acenocoumarol. Acetaminophen Acetaminophen may decrease the excretion rate of Isepamicin which could result in a higher serum level. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- ATC Codes
- J01GB11 — Isepamicin
- Drug Categories
- Agents that produce neuromuscular block (indirect)
- Aminoglycoside Antibacterials
- Anti-Bacterial Agents
- Anti-Infective Agents
- Antibacterials for Systemic Use
- Antiinfectives for Systemic Use
- Carbohydrates
- Drugs that are Mainly Renally Excreted
- Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index
- Glycosides
- Narrow Therapeutic Index Drugs
- Nephrotoxic agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as 2-deoxystreptamine aminoglycosides. These are aminoglycosides containing the 2-deoxystreptamine (1,3-diaminocyclohexane-4,5,6-triol) core.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbohydrates and carbohydrate conjugates
- Direct Parent
- 2-deoxystreptamine aminoglycosides
- Alternative Parents
- O-glycosyl compounds / Beta amino acids and derivatives / Aminocyclitols and derivatives / Cyclohexylamines / Cyclohexanols / Oxanes / Monosaccharides / Tertiary alcohols / Secondary carboxylic acid amides / 1,2-aminoalcohols show 9 more
- Substituents
- 1,2-aminoalcohol / 2-deoxystreptamine aminoglycoside / Acetal / Alcohol / Aliphatic heteromonocyclic compound / Amine / Amino acid or derivatives / Aminocyclitol or derivatives / Beta amino acid or derivatives / Carbonyl group show 25 more
- Molecular Framework
- Aliphatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- G7K224460P
- CAS number
- 58152-03-7
- InChI Key
- UDIIBEDMEYAVNG-ZKFPOVNWSA-N
- InChI
- InChI=1S/C22H43N5O12/c1-22(35)6-36-20(15(33)18(22)26-2)39-17-8(27-19(34)9(28)4-23)3-7(25)16(14(17)32)38-21-13(31)12(30)11(29)10(5-24)37-21/h7-18,20-21,26,28-33,35H,3-6,23-25H2,1-2H3,(H,27,34)/t7-,8+,9-,10+,11+,12-,13+,14-,15+,16+,17-,18+,20+,21+,22-/m0/s1
- IUPAC Name
- (2S)-3-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-{[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy}-2-{[(2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-(methylamino)oxan-2-yl]oxy}-3-hydroxycyclohexyl]-2-hydroxypropanamide
- SMILES
- [H][C@]1(O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@@]3([H])O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H]2O)NC(=O)[C@@H](O)CN)OC[C@](C)(O)[C@H](NC)[C@H]1O
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0041911
- ChemSpider
- 2301019
- ChEMBL
- CHEMBL272080
- ZINC
- ZINC000008214585
- Wikipedia
- Isepamicin
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 63.0 mg/mL ALOGPS logP -2.8 ALOGPS logP -7.3 Chemaxon logS -0.96 ALOGPS pKa (Strongest Acidic) 12.07 Chemaxon pKa (Strongest Basic) 9.54 Chemaxon Physiological Charge 4 Chemaxon Hydrogen Acceptor Count 16 Chemaxon Hydrogen Donor Count 12 Chemaxon Polar Surface Area 297.72 Å2 Chemaxon Rotatable Bond Count 9 Chemaxon Refractivity 128.43 m3·mol-1 Chemaxon Polarizability 56.68 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 230.1157386 predictedDarkChem Lite v0.1.0 [M-H]- 227.89201 predictedDeepCCS 1.0 (2019) [M+H]+ 228.6927386 predictedDarkChem Lite v0.1.0 [M+H]+ 229.61574 predictedDeepCCS 1.0 (2019) [M+Na]+ 228.0671386 predictedDarkChem Lite v0.1.0 [M+Na]+ 235.94469 predictedDeepCCS 1.0 (2019)
Drug created at June 23, 2017 20:43 / Updated at February 21, 2021 18:54